Mid-Day Market Update: Crude Oil Surges 5%; Staffing 360 Solutions Shares Plunge
Midway through trading Monday, the Dow traded up 0.77% to 35,391.72 while the NASDAQ rose 1.35% to 14,912.95. The S&P also rose, gaining 0.95% to 4,484.08.
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
Benzinga’s Top Ratings Upgrades, Downgrades For August 23, 2021
Upgrades
JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the closing price was at $10.41.
Mid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Trillium Therapeutics
Following the market opening Monday, the Dow traded up 0.56% to 35,318.36 while the NASDAQ rose 0.90% to 14,847.67. The S&P also rose, gaining 0.64% to 4,469.94.
HC Wainwright & Co. Downgrades Trillium Therapeutics to Neutral, Lowers Price Target to $18.5
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Trillium Therapeutics (NASDAQ:TRIL) from Buy to Neutral and lowers the price target from $22 to $18.5.
Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights
Pfizer Inc (NYSE:PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ:TRIL) for $18.50 per share, equivalent to an implied equity value of…
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Trillium Therapeutics Q2 EPS $(0.18) Up From $(0.28) YoY
Trillium Therapeutics (NASDAQ:TRIL) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year.